Emergence of Tigecycline Resistant Acinetobacter baumannii From an Intensive Care Unit (ICU) in Tehran

How to Cite:Afsaneh KarmostajShahin Najar PeerayehAli Hatef SalmanianEmergence of Tigecycline Resistant Acinetobacter baumannii From an Intensive Care Unit (ICU) in Tehran.Jundishapur J Microbiol.6(3):215-19.https://doi.org/10.5812/jjm.4710.

Abstract

Background:

Acinetobacter species, specially, Acinetobacter baumannii, is known, as an important opportunistic pathogen, with arnvariety of infections such as pneumonia, bacteraemia, meningitis, urinary tract, skin and soft tissue infections, associated with highrnmortality. High prevalence of multidrug resistance in A. baumannii, limits our therapeutic choices in the treatment of infectionsrncaused by this bacterium.

Objectives:

The current study aimed to determine in vitro activity of tigecycline and colistin against clinical isolates of MDR A. baumannii, from patients admitted in ICUs Tehran hospitals.

Material and Methods:

This study was conducted from March 2009 to November 2010, on a total of 91 Acinetobacter species isolatedrnfrom clinical specimens in ICUs. All isolates were subjected to PCR to detect blaOXA-51-like gene that is unique to A. baumannii. Thernantimicrobial susceptibility for 13 different antibiotics was tested.

Results:

A. baumannii (blaOXA-51-like gene) was detected in 84 (92.30%) isolates.Resistance rates in A. baumannii, were found to bernfor Imipenem 50 (59.52%), Gentamicin 65 (77.38%), Ciprofloxacin 81 (96.42%), Amikacin 44 (52.38%), Cefotaxime 81 (96.42%), Cefepimern69 (82.14%), Ceftazidim 81 (96.42%), Meropenem 74 (88.09%), Trimethoprim - sulfamethoxazole 78 (92.85%), Aztreonam 82 (97.61%),rnColistin and Polymyxin-B 0%. No interpretive criteria have been approved for tigecycline against Acinetobacter spp. so; the results wererninterpreted by the criteria recommended by Jones, and US FDA for Enterobacteriaceae. Resistance rates for tigecycline were 3 (3.57%)rn(Jones criteria) and 19 (22.61%) (FDA criteria).

Conclusions:

It is clear that new antimicrobials are needed to treat MDR A. baumannii. Polymyxins and tigecycline are among the fewrnantibiotics available to treat infections with these bacteria but little was known about the antimicrobial activity of these agents. ThernPresent study provided valuable information about the effects of the above mentioned drugs that can be used for health policy. Itrnshould be noted that there is a need for regular surveillance of bacterial resistance to these antimicrobial agents.

Keywords

Acinetobacter baumannii

Colistin

Tigecycline

FDA criteria

Full Text

Full text is available in PDF

comments

Crossmark

Checking

Share on

Comments

Number of Comments:0

Cited by

Metrics

Get Permission (article level)

Purchasing Reprints

Copyright Clearance Center (CCC) handles bulk orders for article reprints for Brieflands. To place an order for reprints, please click here ( https://www.copyright.com/landing/reprintsinquiryform/ ). Clicking this link will bring you to a CCC request form where you can provide the details of your order. Once complete, please click the ‘Submit Request’ button and CCC’s Reprints Services team will generate a quote for your review.

Search Relations

Author(s):

Afsaneh Karmostaj:[PubMed][Scholar]
Shahin Najar Peerayeh:[PubMed][Scholar]
Ali Hatef Salmanian:[PubMed][Scholar]